Abstract
Importance Contact-tracing studies suggest minimal secondary transmission in schools. However, there are limited school data accounting for asymptomatic cases, particularly late in the 2020/21 school year, and in the context of uninterrupted in-person schooling and widespread community transmission.
Objectives To determine the SARS-CoV-2 seroprevalence in a sample of school staff, compared to the community, and to COVID-19 rates among all students and staff within the same school population.
Design Incident COVID-19 cases among students and school staff using public health data, with an embedded cross-sectional serosurvey among school staff sampled from February 10 to May 15, 2021, comparing to age, sex and geographic location-matched blood donors sampled in January 2021.
Setting Vancouver School District (British Columbia, Canada) from kindergarten to grade 12.
Participants Active school staff enrolled from February 3 to April 23, 2021.
Main outcome measures SARS-CoV-2 antibodies in a sample of school staff using spike (S)-based testing (unvaccinated staff) or N-based serology testing (vaccinated staff).
Results The incidence of COVID-19 cases among students attending in-person was 9.8 per 1,000 students during the 2020/21 school year (N = 47,280 students), and among staff was 13 per 1,000 since the beginning of the pandemic (N = 7,071 active school staff). In total, 1,689 school staff (64% elementary, 28% secondary, 8.3% school board staff or multiple grades) completed the questionnaire, 78.2% had classroom responsibilities, and spent a median of 17.6 hours in class per week [IQR: 5.0 – 25 hours]. Although 21.5% (363/1,686) reported close contact with a COVID-19 case, only 1.4% (24/1688) of the school staff reported having had a positive viral nucleic acid test. Of this group, five believed they acquired the infection at school. The adjusted seroprevalence in staff who gave blood (1,556/1,689, 92.1%) was 2.3% [95%CI: 1.6 – 3.2%] compared to 2.3% [95%CI: 1.7 – 3.0%] in blood donors.
Conclusion and relevance Despite high reported COVID-19 cases among students and staff, and frequent within-school exposures, we found no detectable increase in seroprevalence among school staff above the community seroprevalence. These findings corroborate claims that, with appropriate mitigation strategies, in-person schooling is not associated with significantly increased risk for school staff.
Question What was the prevalence of COVID-19 infections in school staff who maintained in-person schooling during the 2020/21 school year in Vancouver, British Columbia, and how does it compare to the risk of COVID-19 infection in the community.
Findings As of March 4, 2021, the incidence of COVID-19 cases among school staff was 13 per 1,000 (N = 7,071 school staff) since the beginning of the pandemic. In a cross-sectional seroprevalence analysis from February 10 to May 15, 2021, the adjusted seroprevalence among a sample of school staff (N = 1,556) was 2.3% [95%CI: 1.6 – 3.2%], compared to 2.3% [95%CI: 1.7 – 3.0%] in 1:2 age, sex and geographical location (by postal code)-matched reference group of blood donors.
Meaning We found no detectable increase in seroprevalence among school staff above the community seroprevalence. These findings corroborate claims that, with appropriate mitigation strategies in place, in-person schooling is not associated with significantly higher risk for school staff.
Competing Interest Statement
CO is an employee of the Vancouver School District, but the District was not involved in the design, analysis, interpretation of the data, or the drafting of this manuscript; MS has been an investigator on projects funded by GlaxoSmithKline, Merck, Pfizer, Sanofi-Pasteur, Seqirus, Symvivo and VBI Vaccines. All funds have been paid to his institute, and he has not received any personal payments; Authors declare no relevant conflicts of interest.
Clinical Trial
NA
Funding Statement
The study was funded by the Government of Canada via its COVID-19 Immunity Task Force (to PML). PML and LCM receive a salary from the British Columbia Children's Hospital (BCCH) Foundation through the Investigator Grant Award Program. MS is supported via salary awards from the BC Children's Hospital Foundation, the Canadian Child Health Clinician Scientist Program and the Michael Smith Foundation for Health Research. The BC Children's Hospital Healthy Starts Theme provided some seed funding at the beginning of the study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the University of British Columbia Children's and Women's Research Ethics Board (H20-03593).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding: The study was funded by the Government of Canada via its COVID-19 Immunity Task Force (to PML). PML and LCM receive a salary from the British Columbia Children’s Hospital (BCCH) Foundation through the Investigator Grant Award Program. MS is supported via salary awards from the BC Children’s Hospital Foundation, the Canadian Child Health Clinician Scientist Program and the Michael Smith Foundation for Health Research. The BC Children’s Hospital Healthy Starts Theme provided some seed funding at the beginning of the study.
Data Availability
The data will eventually be made publicly available through the COVID-19 Immunity Task Force
